Ebixa

E494106

Ebixa is a brand-name medication containing memantine, used primarily to treat moderate to severe Alzheimer's disease.

Try in SPARQL Jump to: Statements Referenced by

Statements (47)

Predicate Object
instanceOf brand-name medication
memantine-containing medicinal product
actsOn N-methyl-D-aspartate (NMDA) receptors
administrationFrequency once daily (maintenance dose)
ATCCode N06DX01
belongsTo centrally acting anti-dementia drugs
commonAdverseEffect confusion
constipation
dizziness
headache
hypertension
somnolence
contraindication hypersensitivity to memantine
developedBy H. Lundbeck A/S NERFINISHED
dosageForm film-coated tablet
oral solution
drugInteractionCaution amantadine NERFINISHED
dextromethorphan NERFINISHED
ketamine NERFINISHED
other NMDA antagonists
elimination primarily renal excretion
halfLife about 60–80 hours
hasActiveIngredient memantine
improves cognitive function in Alzheimer's disease
global functioning in Alzheimer's disease
indication moderate Alzheimer's disease
severe Alzheimer's disease
isBrandOf memantine hydrochloride
marketingAuthorizationHolder Lundbeck NERFINISHED
marketingAuthorizationRegion European Union NERFINISHED
maximumDailyDose 20 mg memantine (typical in adults)
maySlow clinical deterioration in Alzheimer's disease
metabolism minimally metabolized in the liver
notIndicatedFor mild Alzheimer's disease
pharmacologicalClass NMDA receptor antagonist
regulates glutamatergic neurotransmission
requires prescription
requiresCautionIn severe renal impairment
requiresDoseAdjustmentIn renal impairment
routeOfAdministration oral
targetPopulation adult patients
elderly patients
therapeuticArea geriatrics
neurology
titration requires gradual dose escalation
treats Alzheimer's disease NERFINISHED
usedIn symptomatic treatment of Alzheimer's disease

Referenced by (1)

Full triples — surface form annotated when it differs from this entity's canonical label.

memantine isMarketedUnderBrandName Ebixa
subject surface form: Memantine